Skip to main content
13 August 2026
24 November 2025

Harbour BioMed Advances Global Collaboration with AstraZeneca

Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, announced an update and advancement of its global strategic collaboration with AstraZeneca, originally established in March 2025. The collaboration aims to discover …

24 November 2025

AGC Biologics Signs GMP Manufacturing Agreement Following AAVantgarde’s Series B

AAVantgarde closing a Series B financing round, AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics’ latest advancement in the adeno-associated virus market. Under this agreement, AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgard…

20 November 2025

Nona Biosciences Partners with Pfizer to Accelerate Antibody Discovery

Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I announced a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications. Under the terms of th…

19 November 2025

Roche, Freenome Form Global Partnership for Cancer Detection Technology

Freenome, an early cancer detection company developing blood-based screening tests, announced a strategic collaboration agreement with Roche to commercialize Freenome's cancer screening technology in international markets. In addition, Freenome will evaluate Roche's forthcoming Sequencing by Expansion (SBX) technology…

18 November 2025

Lunit, Labcorp Announce New AI Collaboration in Oncology

Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical ca…

17 November 2025

SanegeneBio Announces Global RNAi Partnership with Eli Lilly

SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced a global research and licensing collaboration with Eli Lilly and Company . The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio's proprietary tissue selective deliver…

Page 22 of 36